{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:32:33Z","timestamp":1771479153332,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006419","name":"EuroQol Research Foundation","doi-asserted-by":"publisher","award":["432-RA"],"award-info":[{"award-number":["432-RA"]}],"id":[{"id":"10.13039\/501100006419","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40273-025-01545-5","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T02:14:48Z","timestamp":1759716888000},"page":"61-72","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Influence of Perspective on the Valuation of the EQ-5D-Y-3L: A Comparison Using the OPUF Tool and a Discrete\u00a0Choice Experiment"],"prefix":"10.1007","volume":"44","author":[{"given":"Jake","family":"Hitch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gayathri","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koonal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5959-8447","authenticated-orcid":false,"given":"David","family":"Mott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"1545_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s40273-023-01327-x","volume":"42","author":"T Peasgood","year":"2024","unstructured":"Peasgood T, Howell M, Raghunandan R, Salisbury A, Sellars M, Chen G, et al. Systematic review of the relative social value of child and adult health. Pharmacoeconomics. 2024;42:177\u201398. https:\/\/doi.org\/10.1007\/s40273-023-01327-x.","journal-title":"Pharmacoeconomics"},{"key":"1545_CR2","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1007\/s11136-015-0971-1","volume":"24","author":"P Kind","year":"2015","unstructured":"Kind P, Klose K, Gusi N, Olivares PR, Greiner W. Can adult weights be used to value child health states? Testing the influence of perspective in valuing EQ-5D-Y. Qual Life Res. 2015;24:2519\u201339. https:\/\/doi.org\/10.1007\/s11136-015-0971-1.","journal-title":"Qual Life Res"},{"key":"1545_CR3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40273-019-00873-7","volume":"38","author":"D Rowen","year":"2020","unstructured":"Rowen D, Rivero-Arias O, Devlin N, Ratcliffe J. Review of valuation methods of preference-based measures of health for economic evaluation in child and adolescent populations: where are we now and where are we going? Pharmacoeconomics. 2020;38:325\u201340. https:\/\/doi.org\/10.1007\/s40273-019-00873-7.","journal-title":"Pharmacoeconomics"},{"key":"1545_CR4","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s40273-020-00909-3","volume":"38","author":"JM Ramos-Go\u00f1i","year":"2020","unstructured":"Ramos-Go\u00f1i JM, Oppe M, Stolk E, Shah K, Kreimeier S, Rivero-Arias O, et al. International valuation protocol for the EQ-5D-Y-3L. Pharmacoeconomics. 2020;38:653\u201363. https:\/\/doi.org\/10.1007\/s40273-020-00909-3.","journal-title":"Pharmacoeconomics"},{"key":"1545_CR5","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40273-018-0615-8","volume":"36","author":"K Ludwig","year":"2018","unstructured":"Ludwig K, Graf von der Schulenburg J-M, Greiner W. German value set for the EQ-5D-5L. Pharmacoeconomics. 2018;36:663\u201374. https:\/\/doi.org\/10.1007\/s40273-018-0615-8.","journal-title":"Pharmacoeconomics"},{"key":"1545_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40273-022-01210-1","volume":"40","author":"TS Fitriana","year":"2022","unstructured":"Fitriana TS, Roudijk B, Purba FD, Busschbach JJV, Stolk E. Estimating an EQ-5D-Y-3L value set for Indonesia by mapping the DCE onto TTO values. Pharmacoeconomics. 2022;40:157\u201367. https:\/\/doi.org\/10.1007\/s40273-022-01210-1.","journal-title":"Pharmacoeconomics"},{"key":"1545_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40273-022-01187-x","volume":"40","author":"S Dewilde","year":"2022","unstructured":"Dewilde S, Roudijk B, Tollenaar NH, Ramos-Go\u00f1i JM. An EQ-5D-Y-3L value set for Belgium. Pharmacoeconomics. 2022;40:169\u201380. https:\/\/doi.org\/10.1007\/s40273-022-01187-x.","journal-title":"Pharmacoeconomics"},{"key":"1545_CR8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40273-020-00994-4","volume":"39","author":"V Prevolnik Rupel","year":"2021","unstructured":"Prevolnik Rupel V, Ogorevc M, Group. EQ-5d-y value set for Slovenia. Pharmacoeconomics. 2021;39:463\u201371. https:\/\/doi.org\/10.1007\/s40273-020-00994-4.","journal-title":"Pharmacoeconomics"},{"issue":"S2","key":"1545_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40273-022-01143-9","volume":"40","author":"S Kreimeier","year":"2022","unstructured":"Kreimeier S, Mott D, Ludwig K, Greiner W. EQ-5D-Y value set for Germany. Pharmacoeconomics. 2022;40(S2):217\u201329. https:\/\/doi.org\/10.1007\/s40273-022-01143-9.","journal-title":"Pharmacoeconomics"},{"key":"1545_CR10","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1177\/0272989X211001859","volume":"41","author":"T Shiroiwa","year":"2021","unstructured":"Shiroiwa T, Ikeda S, Noto S, Fukuda T, Stolk E. Valuation survey of EQ-5D-Y based on the international common protocol: development of a value set in Japan. Med Decis Making. 2021;41:597\u2013606. https:\/\/doi.org\/10.1177\/0272989X211001859.","journal-title":"Med Decis Making"},{"key":"1545_CR11","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s40273-024-01404-9","volume":"42","author":"CM Espirito Santo","year":"2024","unstructured":"Espirito Santo CM, Miyamoto GC, Santos VS, Ben \u00c2J, Finch AP, Roudijk B, et al. Estimating an EQ-5D-Y-3L value set for Brazil. Pharmacoeconomics. 2024;42:1047\u201363. https:\/\/doi.org\/10.1007\/s40273-024-01404-9.","journal-title":"Pharmacoeconomics"},{"key":"1545_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40273-022-01192-0","volume":"40","author":"B Roudijk","year":"2022","unstructured":"Roudijk B, Sajjad A, Essers B, Lipman S, Stalmeier P, Finch AP. A value set for the EQ-5D-Y-3L in the Netherlands. Pharmacoeconomics. 2022;40:193\u2013203. https:\/\/doi.org\/10.1007\/s40273-022-01192-0.","journal-title":"Pharmacoeconomics"},{"key":"1545_CR13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40273-022-01216-9","volume":"40","author":"Z Yang","year":"2022","unstructured":"Yang Z, Jiang J, Wang P, Jin X, Wu J, Fang Y, et al. Estimating an EQ-5D-Y-3L value set for China. Pharmacoeconomics. 2022;40:147\u201355. https:\/\/doi.org\/10.1007\/s40273-022-01216-9.","journal-title":"Pharmacoeconomics"},{"key":"1545_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40273-022-01190-2","volume":"40","author":"F Rencz","year":"2022","unstructured":"Rencz F, Ruzsa G, Bat\u00f3 A, Yang Z, Finch AP, Brodszky V. Value set for the EQ-5D-Y-3L in Hungary. Pharmacoeconomics. 2022;40:205\u201315. https:\/\/doi.org\/10.1007\/s40273-022-01190-2.","journal-title":"Pharmacoeconomics"},{"key":"1545_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12955-025-02402-x","volume":"23","author":"T Pan","year":"2025","unstructured":"Pan T, Roudijk B, Devlin N, Mulhern B, Norman R. An Australian value set for the EQ-5D-Y-3L. Health Qual Life Outcomes. 2025;23:72. https:\/\/doi.org\/10.1186\/s12955-025-02402-x.","journal-title":"Health Qual Life Outcomes"},{"key":"1545_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s40273-022-01214-x","volume":"40","author":"DJ Mott","year":"2022","unstructured":"Mott DJ, Devlin NJ, Kreimeier S, Norman R, Shah KK, Rivero-Arias O. Analytical considerations when anchoring discrete choice experiment values using composite time trade-off data: the case of EQ-5D-Y-3L. Pharmacoeconomics. 2022;40:129\u201337. https:\/\/doi.org\/10.1007\/s40273-022-01214-x.","journal-title":"Pharmacoeconomics"},{"key":"1545_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12955-022-01998-8","volume":"20","author":"N Devlin","year":"2022","unstructured":"Devlin N, Pan T, Kreimeier S, Verstraete J, Stolk E, Rand K, et al. Valuing EQ-5D-Y: the current state of play. Health Qual Life Outcomes. 2022;20:105. https:\/\/doi.org\/10.1186\/s12955-022-01998-8.","journal-title":"Health Qual Life Outcomes"},{"key":"1545_CR18","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s40273-023-01300-8","volume":"41","author":"NJ Devlin","year":"2023","unstructured":"Devlin NJ, Pan T, Sculpher M, Jit M, Stolk E, Rowen D, et al. Using age-specific values for pediatric HRQoL in cost-effectiveness analysis: is there a problem to be solved? If so, how? Pharmacoeconomics. 2023;41:1165\u201374. https:\/\/doi.org\/10.1007\/s40273-023-01300-8.","journal-title":"Pharmacoeconomics"},{"key":"1545_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40273-022-01226-7","volume":"40","author":"N Devlin","year":"2022","unstructured":"Devlin N, Roudijk B, Viney R, Stolk E. EQ-5D-Y-3L value sets, valuation methods and conceptual questions. Pharmacoeconomics. 2022;40:123\u20137. https:\/\/doi.org\/10.1007\/s40273-022-01226-7.","journal-title":"Pharmacoeconomics"},{"key":"1545_CR20","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.jval.2021.01.011","volume":"24","author":"SA Lipman","year":"2021","unstructured":"Lipman SA, Reckers-Droog VT, Kreimeier S. Think of the children: a discussion of the rationale for and implications of the perspective used for EQ-5D-Y health state valuation. Value Health. 2021;24:976\u201382. https:\/\/doi.org\/10.1016\/j.jval.2021.01.011.","journal-title":"Value Health"},{"key":"1545_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2024.117127","volume":"355","author":"PA Powell","year":"2024","unstructured":"Powell PA, Rowen D, Keetharuth A, Mukuria C, Shah K. Who should value children\u2019s health and how? An international Delphi study. Soc Sci Med. 2024;355:117127. https:\/\/doi.org\/10.1016\/j.socscimed.2024.117127.","journal-title":"Soc Sci Med"},{"key":"1545_CR22","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.jval.2022.03.001","volume":"25","author":"JM Ramos-Go\u00f1i","year":"2022","unstructured":"Ramos-Go\u00f1i JM, Est\u00e9vez-Carrillo A, Rivero-Arias O, Rowen D, Mott D, Shah K, et al. Does changing the age of a child to be considered in 3-level version of EQ-5D-Y discrete choice experiment\u2013based valuation studies affect health preferences? Value Health. 2022;25:1196\u2013204. https:\/\/doi.org\/10.1016\/j.jval.2022.03.001.","journal-title":"Value Health"},{"key":"1545_CR23","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s10198-020-01205-9","volume":"21","author":"KK Shah","year":"2020","unstructured":"Shah KK, Ramos-Go\u00f1i JM, Kreimeier S, Devlin NJ. An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values. Eur J Health Econ. 2020;21:1091\u2013103. https:\/\/doi.org\/10.1007\/s10198-020-01205-9.","journal-title":"Eur J Health Econ"},{"key":"1545_CR24","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s10198-021-01377-y","volume":"22","author":"SA Lipman","year":"2021","unstructured":"Lipman SA, Reckers-Droog VT, Karimi M, Jakubczyk M, Attema AE. Self vs. other, child vs. adult. An experimental comparison of valuation perspectives for valuation of EQ-5D-Y-3L health states. Eur J Health Econ. 2021;22:1507\u201318. https:\/\/doi.org\/10.1007\/s10198-021-01377-y.","journal-title":"Eur J Health Econ"},{"key":"1545_CR25","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jval.2021.11.1377","volume":"25","author":"S Dewilde","year":"2022","unstructured":"Dewilde S, Janssen MF, Lloyd AJ, Shah K. Exploration of the reasons why health state valuation differs for children compared with adults: a mixed methods approach. Value Health. 2022;25:1185\u201395. https:\/\/doi.org\/10.1016\/j.jval.2021.11.1377.","journal-title":"Value Health"},{"key":"1545_CR26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12955-021-01858-x","volume":"19","author":"PA Powell","year":"2021","unstructured":"Powell PA, Rowen D, Rivero-Arias O, Tsuchiya A, Brazier JE. Valuing child and adolescent health: a qualitative study on different perspectives and priorities taken by the adult general public. Health Qual Life Outcomes. 2021;19:222. https:\/\/doi.org\/10.1186\/s12955-021-01858-x.","journal-title":"Health Qual Life Outcomes"},{"key":"1545_CR27","doi-asserted-by":"publisher","DOI":"10.12688\/wellcomeopenres.17518.1","volume":"7","author":"PP Schneider","year":"2022","unstructured":"Schneider PP, van Hout B, Heisen M, Brazier J, Devlin N. The online elicitation of personal utility functions (OPUF) tool: a new method for valuing health states. Wellcome Open Res. 2022;7:14. https:\/\/doi.org\/10.12688\/wellcomeopenres.17518.1.","journal-title":"Wellcome Open Res"},{"key":"1545_CR28","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10198-018-0993-z","volume":"20","author":"NJ Devlin","year":"2019","unstructured":"Devlin NJ, Shah KK, Mulhern BJ, Pantiri K, van Hout B. A new method for valuing health: directly eliciting personal utility functions. Eur J Health Econ. 2019;20:257\u201370. https:\/\/doi.org\/10.1007\/s10198-018-0993-z.","journal-title":"Eur J Health Econ"},{"key":"1545_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/23814683221083839","volume":"7","author":"TM Hansen","year":"2022","unstructured":"Hansen TM, Stavem K, Rand K. Sample size and model prediction accuracy in EQ-5D-5L valuations studies: expected out-of-sample accuracy based on resampling with different sample sizes and alternative model specifications. MDM Policy Pract. 2022;7:23814683221083839. https:\/\/doi.org\/10.1177\/23814683221083839.","journal-title":"MDM Policy Pract"},{"key":"1545_CR30","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40271-015-0118-z","volume":"8","author":"EW De Bekker-Grob","year":"2015","unstructured":"De Bekker-Grob EW, Donkers B, Jonker MF, Stolk EA. Sample size requirements for discrete-choice experiments in healthcare: a practical guide. Patient. 2015;8:373\u201384. https:\/\/doi.org\/10.1007\/s40271-015-0118-z.","journal-title":"Patient"},{"key":"1545_CR31","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/00019053-200826080-00004","volume":"26","author":"E Lancsar","year":"2008","unstructured":"Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user\u2019s guide. Pharmacoeconomics. 2008;26:661\u201377. https:\/\/doi.org\/10.2165\/00019053-200826080-00004.","journal-title":"Pharmacoeconomics"},{"key":"1545_CR32","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.jval.2023.12.009","volume":"27","author":"P Schneider","year":"2024","unstructured":"Schneider P, Blankart K, Brazier J, Van Hout B, Devlin N. Using the online elicitation of personal utility functions approach to derive a patient-based 5-level version of EQ-5D value set: a study in 122 patients with rheumatic diseases from Germany. Value Health. 2024;27:376\u201382. https:\/\/doi.org\/10.1016\/j.jval.2023.12.009.","journal-title":"Value Health"},{"key":"1545_CR33","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.jval.2020.04.1831","volume":"21","author":"DJ Mott","year":"2020","unstructured":"Mott DJ, Chami N, Tervonen T. Reporting quality of marginal rates of substitution in discrete choice experiments that elicit patient preferences. Value Health. 2020;21:979\u201384.","journal-title":"Value Health"},{"key":"1545_CR34","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1007\/s11136-025-03989-w","volume":"34","author":"T Peasgood","year":"2025","unstructured":"Peasgood T, Devlin N, Ludwig K, Marten O, McDool E, Schneider P, et al. How well do participants understand the questions asked in the Online Personal Utility Functions (OPUF) approach? A cognitive debrief of the EQ-HWB-S (EQ health and wellbeing short version) valuation. Qual Life Res. 2025;34:2269\u201378. https:\/\/doi.org\/10.1007\/s11136-025-03989-w.","journal-title":"Qual Life Res"},{"key":"1545_CR35","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s11136-024-03618-y","volume":"33","author":"F Xie","year":"2024","unstructured":"Xie F, Xie S, Pullenayegum E, Ohinmaa A. Understanding Canadian stakeholders\u2019 views on measuring and valuing health for children and adolescents: a qualitative study. Qual Life Res. 2024;33:1415\u201322. https:\/\/doi.org\/10.1007\/s11136-024-03618-y.","journal-title":"Qual Life Res"},{"key":"1545_CR36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s40273-022-01222-x","volume":"40","author":"JL Nazari","year":"2022","unstructured":"Nazari JL, Pickard AS, Gu NY. Findings from a roundtable discussion with US stakeholders on valuation of the EQ-5D-Y-3L. Pharmacoeconomics. 2022;40:139\u201346. https:\/\/doi.org\/10.1007\/s40273-022-01222-x.","journal-title":"Pharmacoeconomics"},{"issue":"25","key":"1545_CR37","doi-asserted-by":"publisher","first-page":"02483","DOI":"10.1016\/j.jval.2025.07.016","volume":"S1098\u20133015","author":"T Pan","year":"2025","unstructured":"Pan T, Ramos-Goni JM, Roudijk B, Xie S, Xie F, Yang Z, et al. Testing the valuation of the EQ-5D-Y-5L in adults and adolescents: Results from a five-country study and implications for the descriptive system. Value Health. 2025;S1098\u20133015(25):02483. https:\/\/doi.org\/10.1016\/j.jval.2025.07.016.","journal-title":"Value Health"},{"key":"1545_CR38","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.jval.2025.01.020","volume":"28","author":"JL Nazari","year":"2025","unstructured":"Nazari JL, Ramos-Go\u00f1i JM, Gu NY, Pickard AS. An acquired taste: latent class analysis to compare adolescent and adult preferences for EQ-5D-Y-3L health states. Value Health. 2025;28:781\u20139. https:\/\/doi.org\/10.1016\/j.jval.2025.01.020.","journal-title":"Value Health"},{"key":"1545_CR39","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1177\/0272989X21999607","volume":"41","author":"DJ Mott","year":"2021","unstructured":"Mott DJ, Shah KK, Ramos-Go\u00f1i JM, Devlin NJ, Rivero-Arias O. Valuing EQ-5D-Y-3L health states using a discrete choice experiment: do adult and adolescent preferences differ? Med Decis Making. 2021;41:584\u201396. https:\/\/doi.org\/10.1177\/0272989X21999607.","journal-title":"Med Decis Making"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01545-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01545-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01545-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T04:54:02Z","timestamp":1768366442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01545-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1545"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01545-5","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors received grants from the EuroQol Research Foundation during the conduct of the study. Koonal Shah, Nancy Devlin, and David Mott are members of the EuroQol Group Association. The views expressed in this paper do not reflect those of the EuroQol Group. David Mott is an employee of the Office of Health Economics (OHE), a registered charity, and an Independent Research Organisation, which receives funding from a variety of private and public sector sources. Jake Hitch and Gayathri Kumar were employees of OHE during the conduct of the study. Koonal Shah is employed by the National Institute for Health and Care Excellence (NICE); the views expressed in this paper do not reflect those of NICE. Nancy Devlin and Paul Schneider have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All authors contributed to the study conception and design. The analysis was performed by JH and DM. The first draft of the manuscript was written by JH, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship Statement:"}},{"value":"Ethical approval was sought and received from the City, University of London (now City St George\u2019s, University of London) School of Social Sciences Research Ethics Committee (ETH2223-1011). All participants provided informed consent before participating in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and Informed Consent"}},{"value":"The study materials are available from the corresponding author upon reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}